Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
987 questions in 78 reviews · Haematology
current versionsNo studies 256 · 25.9%Ungraded 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
MSCs vs control/placebo All‐cause mortality (prophylactic trials) (over duration of trial) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their… Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in… (2019) · Cochrane | HR 0.85 [0.5, 1.42] | 5 studies · 301 participants | Low |
MSCs vs control/placebo All‐cause mortality (therapeutic trials) (over duration of trial) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their… Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in… (2019) · Cochrane | HR 1.12 [0.8, 1.56] | 1 study · 244 participants | Very low |
MSCs vs control/placebo Safety of MSC infusion · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their… Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in… (2019) · Cochrane | no estimate extracted | 7 studies · 334 participants | Ungraded |
MSCs vs control/placebo Health‐related quality of life · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their… Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in… (2019) · Cochrane | no estimate extracted | NR | No studies |
MSCs vs control/placebo Relapse of malignant disease (prophylactic trials) (>12‐month · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their… Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in… (2019) · Cochrane | RR 1.08 [0.73, 1.59] | 6 studies · 323 participants | Low |
MSCs vs control/placebo Incidence of acute GvHD (prophylactic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their… Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in… (2019) · Cochrane | RR 0.86 [0.63, 1.17] | 6 studies · 247 participants | Low |
MSCs vs control/placebo Incidence of chronic GvHD (prophylactic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their… Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in… (2019) · Cochrane | RR 0.66 [0.49, 0.89] | 6 studies · 283 participants | Low |
MSCs vs control/placebo Acute GvHD complete response (therapeutic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their… Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in… (2019) · Cochrane | RR 1.16 [0.79, 1.7] | 1 study · 260 participants | Very low |
MSCs vs control/placebo Chronic GvHD complete response (therapeutic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their… Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in… (2019) · Cochrane | RR 5 [0.75, 33.21] | 1 study · 40 participants | Very low |
Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment) All‐cause mortality up to 30 days № of participants: 72 (1 RCT) · patients undergoing non‐cardiac surgery or invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | RR 0.38 [0.13, 1.1] | NR | Very low |
Prophylactic plasma transfusion before surgery/invasive procedures vs alternative haemostatic agents Number of transfusions per participant within 7 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic plasma transfusion before surgery/invasive procedures vs alternative haemostatic agents Number of individuals requiring a transfusion within 7 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic plasma transfusion before surgery/invasive procedures vs alternative haemostatic agents Serious adverse events measured by plasma transfusion‐related complications within 24 hours № of participants: 21 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | RR 9.82 [0.59, 162.24] | NR | Very low |
Prophylactic plasma transfusion before surgery/invasive procedures vs alternative haemostatic agents Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic plasma transfusion before surgery/invasive procedures vs alternative haemostatic agents Quality of life ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Thromboelastography threshold vs standard of care (laboratory parameters) All‐cause mortality up to 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Thromboelastography threshold vs standard of care (laboratory parameters) Major bleeding within 24 hours № of participants: 60 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | RR 0.33 [0.01, 7.87] | NR | Very low |
Thromboelastography threshold vs standard of care (laboratory parameters) Number of transfusions per participant within 7 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Thromboelastography threshold vs standard of care (laboratory parameters) Number of individuals requiring a transfusion within 7 days № of participants: 60 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | RR 0.18 [0.08, 0.39] | NR | Low |
Thromboelastography threshold vs standard of care (laboratory parameters) Serious adverse events measured by plasma transfusion‐related complications within 24 hours № of participants: 60 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | RR 0.33 [0.01, 7.87] | NR | Very low |
Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment) Major bleeding within 24 hours № of participants: 148 (2 RCTs) · patients undergoing non‐cardiac surgery or invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | RR 0.33 | NR | Very low |
Thromboelastography threshold vs standard of care (laboratory parameters) Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Thromboelastography threshold vs standard of care (laboratory parameters) Quality of life ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment) Number of transfusions per participant within 7 days № of participants: 76 (1 RCT) · patients undergoing non‐cardiac surgery or invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | Very low |
Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment) Number of individuals requiring a transfusion within 7 days № of participants: 72 (1 RCT) · patients undergoing non‐cardiac surgery or invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | Very low |
Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment) Serious adverse events measured by plasma transfusion‐related complications within 24 hours № of participants: 76 (1 RCT) · patients undergoing non‐cardiac surgery or invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | Very low |
Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment) Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery or invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic plasma transfusion before surgery/invasive procedures vs no prophylactic plasma transfusion before surgery/invasive procedures (colloid, crystalloid, placebo, or no treatment) Quality of life ‐ not reported · patients undergoing non‐cardiac surgery or invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic plasma transfusion before surgery/invasive procedures vs alternative haemostatic agents All‐cause mortality up to 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | No studies |
Prophylactic plasma transfusion before surgery/invasive procedures vs alternative haemostatic agents Major bleeding within 24 hours № of participants: 21 (1 RCT) · patients undergoing non‐cardiac surgery/invasive procedures Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use… (2019) · Cochrane | no estimate extracted | NR | Very low |
Intervention NR Polyneuropathies · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults… (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Serious adverse events · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults… (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Withdrawals due to adverse events · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults… (2019) · Cochrane | no estimate extracted | 82 participants | Ungraded |
Intervention NR Quality of life · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults… (2019) · Cochrane | no estimate extracted | NR | No studies |
ATRA in addition to chemotherapy vs chemotherapy only Mortality (instead of overall survival) · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL)) Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid… (2018) · Cochrane | HR 0.94 [0.87, 1.02] | 7 studies · 2985 participants | Moderate |
ATRA in addition to chemotherapy vs chemotherapy only Quality of life · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL)) Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid… (2018) · Cochrane | no estimate extracted | NR | No studies |
ATRA in addition to chemotherapy vs chemotherapy only Mortality, relapse and progresses (instead of disease‐ or relapse‐free survival) · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL)) Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid… (2018) · Cochrane | HR 0.99 [0.87, 1.12] | 3 studies · 1258 participants | Moderate |
ATRA in addition to chemotherapy vs chemotherapy only On‐study mortality · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL)) Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid… (2018) · Cochrane | RR 1.02 [0.81, 1.3] | 5 studies · 2839 participants | Moderate |
ATRA in addition to chemotherapy vs chemotherapy only Infection grade III/IV · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL)) Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid… (2018) · Cochrane | RR 1.05 [0.96, 1.15] | 3 studies · 1428 participants | Moderate |
ATRA in addition to chemotherapy vs chemotherapy only Diarrhoea grade III/IV · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL)) Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid… (2018) · Cochrane | RR 2.19 [1.07, 4.47] | 2 studies · 337 participants | Very low |
ATRA in addition to chemotherapy vs chemotherapy only Nausea/vomiting grade III/IV · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL)) Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid… (2018) · Cochrane | RR 1.46 [0.75, 2.85] | 2 studies · 337 participants | Very low |
ATRA in addition to chemotherapy vs chemotherapy only Cardiac toxicity grade III/IV · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL)) Effects of all‐trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid… (2018) · Cochrane | RR 0.46 [0.24, 0.9] | 3 studies · 1428 participants | Very low |
Platelet transfusion vs no platelet transfusion Major procedure‐related bleeding within 24 hours of the procedure · People with thrombocytopenia Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of… (2018) · Cochrane | no estimate extracted | 2 studies · 150 participants | Very low |
Platelet transfusion vs no platelet transfusion All‐cause mortality up to 30 days after the procedure · People with thrombocytopenia Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of… (2018) · Cochrane | no estimate extracted | NR | No studies |
Platelet transfusion vs no platelet transfusion Transfusion‐related complications within 24 hours of the procedure · People with thrombocytopenia Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of… (2018) · Cochrane | no estimate extracted | NR | No studies |
Platelet transfusion vs no platelet transfusion Procedure‐related (lumbar puncture or epidural anaesthetic) complications within 7 days of the procedure · People with thrombocytopenia Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of… (2018) · Cochrane | no estimate extracted | 1 study · 21 participants | Very low |
Platelet transfusion vs no platelet transfusion Quality of life (as defined by the individual studies) · People with thrombocytopenia Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of… (2018) · Cochrane | no estimate extracted | NR | No studies |
Nivolumab vs no other intervention OS · adults with Hodgkin's lymphoma Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) (2018) · Cochrane | no estimate extracted | 2 studies · 260 participants | Very low |
Nivolumab vs no other intervention QoL · adults with Hodgkin's lymphoma Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) (2018) · Cochrane | no estimate extracted | 1 study · 80 participants | Very low |
Nivolumab vs no other intervention PFS · adults with Hodgkin's lymphoma Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) (2018) · Cochrane | no estimate extracted | 3 studies · 283 participants | Very low |